In LBD biofluid studies, GFAP levels in blood and CSF are higher than controls, similar to AD, variably different from other neurodegenerative diseases, and may be associated with cognitive performance [126,127,128,129,130]. The gene discussed is GFAP; the disease is Alzheimer disease.